Tania Sánchez‐Pérez

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Víctor Moreno, María Vieito, Tatiana Hernández‐Guerrero et al. · Annals of Oncology · 2020 · 66 citations · Full text

Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents

Tania Sánchez‐Pérez, Gustavo Ortiz-Ferrón, Abelardo López‐Rivas · Cell Death and Differentiation · 2009 · 52 citations · Full text

Antimicrotubule Agents, Immunology, Cell Death +8

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies

Rodrigo A. Toledo, Elena Garralda, Maria Mitsi et al. · Clinical Cancer Research · 2018 · 47 citations

Clinical activity of <scp>CC‐90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies

Antoine Hollebecque, Stefania Salvagni, Ruth Plummer et al. · Cancer · 2022 · 45 citations · Full text

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Antoine Hollebecque, Stefania Salvagni, Ruth Plummer et al. · Clinical Cancer Research · 2020 · 42 citations · Full text